The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Prevention of Type 2 Diabetes Mellitus Through Inhibition of the Renin-Angiotensin System
Abstract
Type 2 diabetes mellitus is becoming a major health problem associated with excess morbidity and mortality. As the prevalence of type 2 diabetes is rapidly increasing, prevention of the disease should be considered as a key objective in the near future. Besides lifestyle changes, various pharmacological treatments have proven their efficacy in placebo-controlled clinical trials, including antidiabetic drugs such as metformin, acarbose and troglitazone, or antiobesity agents such as orlistat. Arterial hypertension, a clinical entity in which insulin resistance is common, is strongly associated with type 2 diabetes and may precede the disease by several years. While antihypertensive agents such as diuretics or beta-adrenoceptor antagonists may worsen insulin resistance and impair glucose tolerance, newer antihypertensive agents exert neutral or even slightly positive metabolic effects. Numerous clinical trials have investigated the effects of ACE inhibitors or angiotensin II receptor antagonists (ARAs) on insulin sensitivity in hypertensive patients, with or without diabetes, with no consistent results. Almost half of the studies with ACE inhibitors in hypertensive nondiabetic individuals demonstrated a slight but significant increase in insulin sensitivity as assessed by insulin-stimulated glucose disposal during a euglycaemic hyperinsulinaemic clamp, while the other half failed to reveal any significant change. The effects of ARAs on insulin sensitivity are neutral in most studies. Mechanisms of improvement of glucose tolerance and insulin sensitivity through the inhibition of the renin-angiotensin system (RAS) are complex. They may include improvement of blood flow and microcirculation in skeletal muscles and, thereby, enhancement of insulin and glucose delivery to the insulin-sensitive tissues, facilitating insulin signalling at the cellular level and improvement of insulin secretion by the beta cells. Six recent large-scale clinical studies reported a remarkably consistent reduction in the incidence of type 2 diabetes in hypertensive patients treated with either ACE inhibitors or ARAs for 3-6 years, compared with a thiazide diuretic, beta-adrenoceptor antagonist, the calcium channel antagonist amlodipine or even placebo. The relative risk reduction averaged 14% (p = 0.034) in the CAPPP (Captopril Prevention Project) with captopril compared with a thiazide or beta1-adrenoceptor antagonist, 34% (p < 0.001) in the HOPE (Heart Outcomes Prevention Evaluation) study with ramipril compared with placebo, 30% (p < 0.001) in the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) with lisinopril compared with chlortalidone, 25% (p < 0.001) in the LIFE (Losartan Intervention For Endpoint reduction in hypertension study) with losartan compared with atenolol, and 25% (p = 0.09) in the SCOPE (Study on Cognition and Prognosis in the Elderly) with candesartan cilexetil compared with placebo, and 23% (p < 0.0001) in the VALUE (Valsartan Antihypertensive Long-term Use Evaluation) trial with valsartan compared with amlodipine. All these studies considered the development of diabetes as a secondary endpoint, except the HOPE trial where it was a post hoc analysis. These encouraging observations led to the initiation of two large, prospective, placebo-controlled randomised clinical trials whose primary outcome is the prevention of type 2 diabetes: the DREAM (Diabetes REduction Approaches with ramipril and rosiglitazone Medications) trial with the ACE inhibitor ramipril and the NAVIGATOR (Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research) trial with the ARA valsartan. Finally, ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) will also investigate as a secondary endpoint whether it is possible to prevent the development of type 2 diabetes by blocking the RAS with either an ACE inhibitor or an ARA or a combination of both. Thus, the recent consistent observations of a 14-34% reduction of the development of diabetes in hypertensive patients receiving ACE inhibitors or ARAs are exciting. From a theoretical point of view, they emphasise that there are many aspects of the pathogenesis, prevention and treatment of type 2 diabetes that still need to be uncovered. From a practical point of view, they may offer a new strategy to reduce the ongoing epidemic and burden of type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, inhibition of the renin-angiotensin system with ACE inhibitors or angiotensin receptor blockers (ARBs) may lower risk for diabetes itself.171”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [171]
Citations
Cites
1 retracted
Effect of Captopril, Losartan, and Bradykinin on Early Steps of Insulin Action
Carvalho, C. R. D. O., Thirone, A. C. P., Gontijo, J. A. R., Velloso, L. A., & Saad, M. J. A. (1997) · Diabetes · doi:10.2337/diab.46.12.1950 · Cited by 117
RetractedChobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Research works printed but not linked: 13
- McFarlane, 2001, J Clin Endocrinol Metab, 86, 713
- Medalie, 1975, Arch Intern Med, 135, 811, 10.1001/archinte.1975.00330060055007 · DOI · Paper page
- 1994, World Health Organ Tech Rep Ser, 844, 1
- Scheen, 2002, Med Hyg, 60, 1480
- Paquot, 1995, Med Hyg, 53, 1633
- Scheen, 2001, Diabetes Metab, 27, 193
- Lefebvre, 1995, Clin Invest Med, 18, 340
- Tiret, 1992, Am J Hum Genet, 51, 197
- Petrie, 2000, J Clin Endocrinol Metab, 85, 1882
- Paolisso, 1995, J Hum Hypertens, 9, 541
- Paolisso, 1992, J Hum Hypertens, 6, 175
- Richey, 1999, Am J Physiol, 277, E920
- Henriksen, 1999, Am J Physiol, 277, R332
Cited by
Sorted by citations
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,317
Eckel, R. H., Grundy, S. M., & Zimmet, P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,755
Grundy, S. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,227
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Diagnosis and management of the metabolic syndrome
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000200416.65370.a0 · Cited by 437
Obesity-Related Hypertension: Epidemiology, Pathophysiology, and Clinical Management
Kotchen, T. A. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.172 · Cited by 418
Aldosterone and end-organ damage
Brown, N. J. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000165889.60254.98 · Cited by 321
New-onset diabetes and antihypertensive drugs
Mancia, G., Grassi, G. M., & Zanchetti, A. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000194119.42722.21 · Cited by 291
Ballestri, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1724 · Cited by 266
PPARγ-Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin
Clasen, R., Schupp, M., Foryst‐Ludwig, A., Sprang, C., Clemenz, M., Krikov, M., Thöne‐Reineke, C., Unger, T., & Kintscher, U. (2005) · Hypertension · doi:10.1161/01.hyp.0000168046.19884.6a · Cited by 257
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. J. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70146-5 · Cited by 251
Self-citationPépin, J.-L., Tamisier, R., Barone-Rochette, G., Launois, S. H., Lévy, P., & Baguet, J.-P. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1803oc · Cited by 232
Aldosterone and end-organ damage
Marney, A. M., & Brown, N. J. (2007) · Clinical Science · doi:10.1042/cs20070123 · Cited by 234
Gillespie, E. L., White, C. M., Kardas, M. J., LINDBERG, M. C., & Coleman, C. I. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2261 · Cited by 217
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. J. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70147-7 · Cited by 199
Self-citationThe renin–angiotensin–aldosterone system and glucose homeostasis
Luther, J. M., & Brown, N. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.006 · Cited by 185
Oxidative Stress as Pathogenesis of Cardiovascular Risk Associated with Metabolic Syndrome
Otani, H. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3739 · Cited by 185
Mori, J., Alrob, O. A., Wagg, C. S., Harris, R. A., Lopaschuk, G. D., & Oudit, G. Y. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00636.2012 · Cited by 169
Krentz, A. J., Clough, G. F., & Byrne, C. D. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00670.x · Cited by 171
Renin‐Angiotensin‐Aldosterone System in Diabetes and Hypertension
Hsueh, W. A., & Wyne, K. L. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00449.x · Cited by 166
Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects
Miura, S.-I., Karnik, S. S., & Saku, K. (2010) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310370852 · Cited by 154
Drug Interactions of Clinical Importance with Antihyperglycaemic Agents
Scheen, A. J. (2005) · Drug Safety · doi:10.2165/00002018-200528070-00004 · Cited by 146
Self-citationApproaches to prevention of cardiovascular complications and events in diabetes mellitus
Coccheri, S. (2007) · Drugs · doi:10.2165/00003495-200767070-00005 · Cited by 139
Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists
Erbe, D. V., Gartrell, K., Zhang, Y., Suri, V., Kirincich, S. J., Will, S., Perreault, M., Wang, S., & Tobin, J. F. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.05.002 · Cited by 135
Black, H. R., Davis, B. R., Barzilay, J. I., Nwachuku, C., Baimbridge, C., Marginean, H., Wright, J. T., Basile, J., Wong, N. D., Whelton, P. K., et al. (2008) · Diabetes Care · doi:10.2337/dc07-1452 · Cited by 116
The multi‐faceted cross‐talk between the insulin and angiotensin II signaling systems
Velloso, L. A., Folli, F. B., Perego, L., & Saad, M. J. A. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.611 · Cited by 113
Imayama, I., Ichiki, T., Inanaga, K., OHTSUBO, H., FUKUYAMA, K., ONO, H., Hashiguchi, Y., & Sunagawa, K. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.07.014 · Cited by 114
Liang, T., Wu, L., Xi, Y., Li, Y., Xie, X., Fan, C., Yang, L., Yang, S., Chen, X., Zhang, J., et al. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1764488 · Cited by 111
Hove, K. D., Brøns, C., Færch, K., Lund, S. S., Rossing, P. R., & Vaag, A. A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0554 · Cited by 110
Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets
Luther, J. M., Luo, P., Kreger, M. T., Brissova, M., Dai, C., Whitfield, T. T., Kim, H. S., Wasserman, D. H., Powers, A. C., & Brown, N. J. (2011) · Diabetologia · doi:10.1007/s00125-011-2158-9 · Cited by 109
Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice
Niu, M.-J., Yang, J., Lin, S., Ji, X., & Guo, L. (2008) · Endocrine · doi:10.1007/s12020-008-9110-x · Cited by 108
Insulin Resistance, Inflammatory Biomarkers, and Adipokines in Patients with Chronic Kidney Disease
de Vinuesa, S. G., Goicoechea, M., Kanter, J., Puerta, M., Cachofeiro, V., Lahera, V., Gómez-Campderá, F. J., & Luño, J. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080916 · Cited by 108
Metformin, beyond an insulin sensitizer, targeting heart and pancreatic β cells
Yang, X., Xu, Z., Zhang, C., Cai, Z., & Zhang, J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.019 · Cited by 108
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension
Benndorf, R. A., Rudolph, T. K., Appel, D., Schwedhelm, E., Maas, R., Schulze, F., Silberhorn, E., & Böger, R. H. (2006) · Metabolism · doi:10.1016/j.metabol.2006.04.013 · Cited by 100
Chai, W., Wang, W., Liu, J., Barrett, E. J., Carey, R. M., Cao, W., & Liu, Z. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.145409 · Cited by 89
Salem, C. B., Fathallah, N., Hmouda, H., & Bouraoui, K. (2010) · Drug Safety · doi:10.2165/11538290-000000000-00000 · Cited by 91
Lupi, R., Guerra, S. D., Bugliani, M., Boggi, U., Mosca, F., Torri, S., Prato, S. D., & Marchetti, P. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02086 · Cited by 87
Ayers, K. I., Byrne, L. M., Dematteo, A. C., & Brown, N. J. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.189589 · Cited by 84
Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Durante, A., Peretto, G., Laricchia, A., Ancona, F., Spartera, M., Mangieri, A., & Cianflone, D. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799436467 · Cited by 78
The renin-angiotensin system and insulin resistance
Liu, Z. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0007-5 · Cited by 76
Molavi, B., Chen, J., & Mehta, J. L. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00926.2005 · Cited by 72
Effect of Antihypertensive Agents on the Development of Type 2 Diabetes Mellitus
Stump, C. S., Hamilton, M. T., & Sowers, J. R. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.6.796 · Cited by 69
Review article: the metabolic syndrome and non‐alcoholic fatty liver disease
LORIA, P., Lonardo, A., Carulli, L., VERRONE, A. M., Ricchi, M., Lombardini, S., Rudilosso, A., Ballestri, S., & Carulli, N. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02592.x · Cited by 65
The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?
Diamant, M., & Tushuizen, M. E. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0061-4 · Cited by 64
Preuss, H. G., Echard, B. W., Yamashita, E., & Perricone, N. V. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.126 · Cited by 65
Angiotensin inhibition stimulates PPARγ and the release of visfatin
Storka, A., Vojtassakova, E., Mueller, M., Kapiotis, S., Haider, D. G., Jungbauer, A., & Wolzt, M. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02025.x · Cited by 62
Reduced water intake deteriorates glucose regulation in patients with type 2 diabetes
Johnson, E. C., Bardis, C. N., Jansen, L. T., Adams, J. D., Kirkland, T. W., & Kavouras, S. A. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.05.004 · Cited by 67
Mechanisms linking the renin-angiotensin system, obesity, and breast cancer
Rasha, F. A., Ramalingam, L., Gollahon, L., Rahman, R. L., Rahman, S. M., Menikdiwela, K. R., & Moustaïd‐Moussa, N. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0314 · Cited by 65
Rahimi, Z., Moradi, M., & Nasri, H. (2014) · Europe PMC (PubMed Central) · Cited by 61
Renal mitochondrial impairment is attenuated by AT 1 blockade in experimental Type I diabetes
de Cavanagh, E. M. V., Ferder, L., Toblli, J. E., Piotrkowski, B., Stella, I., Fraga, C. G., & Inserra, F. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00926.2007 · Cited by 54
Drug-Induced Endocrine and Metabolic Disorders
Ronald, C. W., Kong, A. P. S., Chan, N. N., Tong, P. C. Y., & Chan, J. C. N. (2007) · Drug Safety · doi:10.2165/00002018-200730030-00005 · Cited by 55
Sharma, A. M., & Engeli, S. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.0197-3118.2006.05422.x · Cited by 53
Telmisartan Improves Endothelial Function in Patients With Essential Hypertension
Benndorf, R. A., Appel, D., Maas, R., Schwedhelm, E., Wenzel, U. O., & Böger, R. H. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31811dfbe7 · Cited by 53
Zarouk, W. A., Hussein, I. R., Esmaiel, N. N., Raslan, H. M., A., H. A., Moguib, O., Emara, N. A., Aly, A. A., & Hamed, M. (2012) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2012_003 · Cited by 53
Goyal, B. R., Parmar, K., Goyal, R. K., & Mehta, A. A. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70611-9 · Cited by 50
Morales, M. G., Ábrigo, J., Meneses, C., Simón, F., Cisternas, F., Rivera, J. C. A., Vázquez, Y., & Cabello‐Verrugio, C. (2014) · Clinical Science · doi:10.1042/cs20130585 · Cited by 51
Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors
Brown, N. J. (2010) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944710379126 · Cited by 49
The renin–angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts
Ferrario, C. M., Groban, L., Wang, H., Sun, X., VonCannon, J. L., Wright, K. N., & Ahmad, S. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.002 · Cited by 47
Fonseca, V. A. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05583.x · Cited by 47
ACE2 deficiency shifts energy metabolism towards glucose utilization
Bernardi, S., Tikellis, C., Candido, R., Tsorotes, D., Pickering, R. J., Bossi, F., Carretta, R., Fabris, B., Cooper, M. E., & Thomas, M. C. (2014) · Metabolism · doi:10.1016/j.metabol.2014.11.004 · Cited by 46
An update on the islet renin–angiotensin system
Cheng, Q., & Leung, P. S. (2011) · Peptides · doi:10.1016/j.peptides.2011.03.003 · Cited by 43
Sušić, D., & Varagić, J. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.008 · Cited by 45
Review article: pancreatic renin-angiotensin systems in health and disease
Skipworth, J. R. A., Szabadkai, G., Damink, S. W. M. O., Leung, P. S., Humphries, S. E., & Montgomery, H. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04810.x · Cited by 42
Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus
McGuire, D. K., Winterfield, J. R., Rytlewski, J., & Ferrannini, E. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.011 · Cited by 42
Phosphodiesterase 5 Inhibition Improves β-Cell Function in Metabolic Syndrome
Hill, K. D., Eckhauser, A. W., Marney, A., & Brown, N. J. (2009) · Diabetes Care · doi:10.2337/dc08-1862 · Cited by 40
Renin–angiotensin–aldosterone system in insulin resistance and metabolic syndrome
Das, U. N. (2016) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2016-0022 · Cited by 39
Plosker, G. L., & Robinson, D. M. (2008) · Drugs · doi:10.2165/00003495-200868030-00008 · Cited by 38
Nutritive blood flow as an essential element supporting muscle anabolism
Clark, M. G., Rattigan, S., & Barrett, E. J. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000222097.90890.c2 · Cited by 39
Review: The therapeutic role of RAS blockade in chronic heart failure
Werner, C. M., & Böhm, M. (2008) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944708091777 · Cited by 39
Is prevention of Type-2 diabetes feasible and efficient in primary care?
Lauritzen, T., Borch‐Johnsen, K., & Sandbæk, A. (2007) · Primary care diabetes · doi:10.1016/j.pcd.2006.11.001 · Cited by 37
ACE inhibitors as a therapy for sarcopenia — Evidence and possible mechanisms
Sumukadas, D., Witham, M. D., Struthers, A. D., & McMurdo, M. E. T. (2008) · The journal of nutrition health & aging · doi:10.1007/bf02982709 · Cited by 39
Treating insulin resistance: future prospects
Bailey, C. J. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.002 · Cited by 37
Bourebaba, Y., Mularczyk, M., Marycz, K., & Bourebaba, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111113 · Cited by 39
Perspectives on the Potential Benefits of Antihypertensive Peptides towards Metabolic Syndrome
Jahandideh, F., & Wu, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062192 · Cited by 36
The role of inflammation in diabetic cardiomyopathy
Reis, F., Nunes, Soares, & Pereira (2012) · International Journal of Interferon Cytokine and Mediator Research · doi:10.2147/ijicmr.s21679 · Cited by 36
Angiotensin (1–7) counteracts the negative effect of angiotensin II on insulin signalling in HUVECs
Tassone, E. J., Sciacqua, A., Andreozzi, F., Presta, I., Perticone, M., Carnevale, D., Casaburo, M., Hribal, M. L., Sesti, G., & Perticone, F. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt065 · Cited by 34
Renin–angiotensin-system blockade in the prevention of diabetes
Östergren, J. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.01.018 · Cited by 34
Prediabetes: a must to recognise disease state
Shehab-Eldin, W. A., Emara, M., & Shoker, A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01705.x · Cited by 33
Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM)
Souto, S. B., Souto, E. B., Braga, D. C., & Medina, J. L. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1038-z · Cited by 36
Wang, N., Chai, W., Zhao, L., Tao, L., Cao, W., & Liu, Z. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00537.2012 · Cited by 33
Tagami, T., Yamamoto, H., Moriyama, K., Sawai, K., Usui, T., Shimatsu, A., & Naruse, M. (2009) · Endocrinology · doi:10.1210/en.2008-0502 · Cited by 35
Ribeiro, A. B. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x75041 · Cited by 33
Roubíček, T., Dolinkova, M., Bláha, J., Haluzíková, D., Bošanská, L., Mráz, M., Křemen, J., & Haluzı́k, M. (2008) · Physiological Research · doi:10.33549/physiolres.931315 · Cited by 33
McCall, K. L., Craddock, D., & Edwards, K. L. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.9.1297 · Cited by 31
Lee, J. W., Gu, H.-O., Jung, Y., Jung, Y., Seo, S., Hong, J. H., Hong, I., Lee, D. H., Kim, O., & Oh, B. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00982-6 · Cited by 33
Inhibiting angiotensin type 1 receptors as a target for diabetes
Kintscher, U., Foryst‐Ludwig, A., & Unger, T. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.10.1257 · Cited by 29
Ferrari, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802576302 · Cited by 27
Chu, K. Y., Cheng, Q., Chen, C., Au, L. S., Seto, S. W., Tuo, Y., Motin, L. G., Kwan, Y. W., & Leung, P. S. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00575.2008 · Cited by 28
Pancreatic Islet Responses to Metabolic Trauma
Burke, S. J., Karlstad, M. D., & Collier, J. J. (2016) · Shock · doi:10.1097/shk.0000000000000607 · Cited by 28
Kitamura, N., Takahashi, Y., Yamadate, S., & Asai, S. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-26 · Cited by 28
Leung, P. S., & de Gasparo, M. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2006.05460.x · Cited by 28
Hellstrom, H. R. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.05.031 · Cited by 27
Senanayake, P. D., Bonilha, V. L., Peterson, J. W., Yamada, Y., Karnik, S. S., Daneshgari, F., Brosnihan, K. B., & Hollyfield, J. G. (2018) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320318789323 · Cited by 27
Pathogenesis, Risk Assessment and Prevention of Type 2 Diabetes mellitus
Joost, H. (2008) · Obesity Facts · doi:10.1159/000137673 · Cited by 27
Karagiannis, A. I., Mikhailidis, D. P., Athyros, V. G., Kakafika, A. I., Τζιόμαλος, Κ., Liberopoulos, E. N., Florentin, M., & Elisaf, M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.191 · Cited by 28
Luther, J. M., Byrne, L. M., Yu, C., Wang, T. J., & Brown, N. J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2122 · Cited by 26
Kanasaki, M., Nagai, T., Kitada, M., Koya, D., & Kanasaki, K. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-25 · Cited by 26
Athyros, V. G., Elisaf, M., Alexandrides, T. K., Achimastos, A. D., Ganotakis, E. S., Bilianou, E., Karagiannis, A. I., Liberopoulos, E. N., Τζιόμαλος, Κ., Mikhailidis, D. P., et al. (2011) · Angiology · doi:10.1177/0003319711421341 · Cited by 26
Milionis, H. J., Kostapanos, M. S., Vakalis, K., Theodorou, I., Bouba, I., Kalaitzidis, R., Georgiou, I. A., Elisaf, M., & Siamopoulos, K. C. (2007) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2007.027 · Cited by 26
Metadata
- Authors
- Scheen, A. J.
- Affiliations
- University of Liège (BE)
- Corresponding author
- Scheen, Andr?? J
- Venue
- Drugs
- Published
- 2004
- Volume
- 64
- Issue
- 22
- Pages
- 2537-2565
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W1561463821
- Cited by
- 293
- References
- 222
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 7 · 2019: 4 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 6 · 2014: 12 · 2013: 8 · 2012: 11
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- type 2 diabetes prevention, renin-angiotensin system, ACE inhibitors, angiotensin receptor blockers, hypertension, insulin sensitivity, glucose tolerance, captopril, ramipril, amlodipine, thiazide diuretics, beta-blockers, insulin resistance, beta-cell function, microcirculation, hope
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypertension, Insulin Resistance, Renin-Angiotensin System, Randomized Controlled Trials as Topic, Angiotensin II Type 2 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
